A National Cancer Clinical Trials System for the 21st Century Reinvigorating the NCI Cooperative Group Program (2010) / Chapter Skim
Currently Skimming:
Appendix B: Committee Member and Staff Biographies
Appendix B: Committee Member and Staff Biographies
Pages 259-274
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 259... ...
, combines experience in clinical and laboratory research with administrative expertise in preparing the University of Texas M.D. Anderson Cancer Center for the next century.
|
From page 260... ...
Dr. Mendelsohn served as the founding editor-inchief of Clinical Cancer Research, a monthly translational research journal published by the American Association for Cancer Research, and he has been a member of the editorial boards of other leading scientific journals.
|
From page 261... ...
McGraw Memorial Chair for Cancer Research at the University of Texas M.D. Anderson Cancer Center, where he is head of the Division of Quantitative Sciences and chair of the Department of Biostatistics.
|
From page 262... ...
Dr. Berry is a statistics editor for the Journal of the National Cancer Institute, associate editor for Breast Cancer Research and Treatment and Clinical Cancer Research, and is a fellow of the American Statistical Association and of the Institute of Mathematical Statistics.
|
From page 263... ...
One research stream, funded by NCI, is to apply management principles to significantly reduce the time steps required to open oncology clinical trials. That research has completed in-depth examinations of four NCI-designated comprehensive Cancer Centers, two major oncology Cooperative Groups, and the NCI Cancer Therapy Evaluation Program and the NCI central institutional review board.
|
From page 264... ...
While at Genentech, her responsibilities included overseeing the Genentech oncology pipeline, including the clinical trials that led to the approvals of trastuzumab (Herceptin) , a humanized antibody for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer; rituximab (Rituxan)
|
From page 265... ...
Clinical Trials Advisory Committee and is co-chair of the Clinical Trials Subcommittee of the NCI Community Cancer Centers Program. He is the recipient of the 2007 Association of Community Cancer Centers David King Community Clinical Scientist Award.
|
From page 266... ...
Liu, M.D., is an associate professor of medicine and oncology and director of translational breast cancer research at Georgetown University Hospital's Lombardi Comprehensive Cancer Center. She also serves on the Breast Correlative Science Working Group and the Breast Committee of the Cancer and Leukemia Group B Cooperative Group.
|
From page 267... ...
Her roles extend nationally, including chairing the Breast Committee for the North Central Cancer Treatment Group, as well as other positions within the American Association for Cancer Research, the American Society of Clinical Oncology, and the National Cancer Institute.
|
From page 268... ...
Dr. Perez is a recipient of the Breast Cancer Research Foundation Research Grant Award (1998–2010)
|
From page 269... ...
She serves on the National Cancer Institute Board of Scientific Advisors; the National Institutes of Health Foundation Board, chairing its PublicPrivate Partnerships Committee; and the American Association for Cancer Research Foundation Board.
|
From page 270... ...
She has been an active participant in professional societies, including the American Association of Cancer Research, where she served on the board of directors and was chair of Women in Cancer Research, and the American Society of Clinical Oncology. She has reviewed manuscripts for many medical journals and served as an associate editor of Clinical Cancer Research, Journal of Clinical Oncology, and Molecular Cancer Therapeutics.
|
From page 271... ...
Erin balogh, M.P.H., joined the Institute of Medicine in August 2008 as a research associate for the National Cancer Policy Forum and Board on Health Care Services. She has worked on two committee studies, the Qualification of Biomarkers and Surrogate Endpoints in Chronic Disease and Cancer Clinical Trials and the NCI Cooperative Group Program.
|
From page 272... ...
She has served as an adviser to the National Cancer Institute and the Food and Drug Administration. At the IOM, she is working on projects relating to national cancer policy, cancer clinical trials, the oncology workforce, and the learning health care system for cancer.
|
From page 273... ...
From May 2005 until September 2009, Dr. Herdman directed the IOM National Cancer Policy Forum, which includes federal and privatesector agencies or organizations relevant to cancer, in addition to academic/ industry members.
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.